JP Morgan Cuts Celgene Rating
Analyst Franklin Berger thinks Celgene's drug-trial delay will affect FDA approval -- and thus, sales -- of another up-and-coming treatment
JP Morgan downgraded Celgene Corp. (CELG ) to long-term buy from buy.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.